ACXP vs. CLSE
ACXP (Acurx Pharmaceuticals, Inc.) is a stock, while CLSE (Convergence Long/Short Equity ETF) is Long-Short fund actively managed by Convergence. Over the past 3 years, ACXP returned -66.87%/yr vs 29.42%/yr for CLSE. Their 0.08 correlation means their historical movements had little consistent relationship.
Performance
ACXP vs. CLSE - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ACXP achieves a -42.17% return, which is significantly lower than CLSE's 24.37% return.
ACXP
- 1D
- 1.41%
- 1M
- -10.00%
- 6M
- -39.11%
- YTD
- -42.17%
- 1Y
- -76.55%
- 3Y*
- -66.87%
- 5Y*
- -58.26%
- 10Y*
- —
- ALL TIME*
- -57.93%
CLSE
- 1D
- 0.24%
- 1M
- 2.19%
- 6M
- 20.32%
- YTD
- 24.37%
- 1Y
- 44.25%
- 3Y*
- 29.42%
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- 20.44%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $106.69K | $141.74K | $162.46K | |
| $15.17M | $11.74M | $9.80M |
ACXP vs. CLSE - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
ACXP Acurx Pharmaceuticals, Inc. | -42.17% | -84.71% | -78.75% | -3.77% | -2.93% |
CLSE Convergence Long/Short Equity ETF | 24.37% | 20.44% | 35.54% | 17.54% | -4.38% |
Correlation
The correlation between ACXP and CLSE is 0.12, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.12 |
Correlation (3Y) Balances recent behavior with more history. | 0.07 |
Correlation (All Time) Calculated using the full available price history since Feb 22, 2022 | 0.08 |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ACXP vs. CLSE — Risk / Return Rank
ACXP
CLSE
ACXP vs. CLSE - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Acurx Pharmaceuticals, Inc. (ACXP) and Convergence Long/Short Equity ETF (CLSE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ACXP | CLSE | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -3.51 | ||
| Sortino ratioReturn per unit of downside risk | -4.52 | ||
| Omega ratioGain probability vs. loss probability | 0.97 | 1.53 | -0.56 |
| Calmar ratioReturn relative to maximum drawdown | -0.94 | 8.77 | -9.71 |
| Martin ratioReturn relative to average drawdown | -1.29 | 29.59 | -30.89 |
Loading charts...
Drawdowns
ACXP vs. CLSE - Drawdown Comparison
The maximum ACXP drawdown since its inception was -99.14%, which is greater than CLSE's maximum drawdown of -16.45%. Use the drawdown chart below to compare losses from any high point for ACXP and CLSE.
Loading charts...
Drawdown Indicators
| ACXP | CLSE | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.14% | -16.45% | -82.69% |
Max Drawdown (1Y)Largest decline over 1 year | -83.33% | -4.85% | -78.48% |
Max Drawdown (3Y)Largest decline over 3 years | -98.83% | -16.45% | -82.38% |
Max Drawdown (5Y)Largest decline over 5 years | -98.84% | — | — |
Current DrawdownCurrent decline from peak | -99.09% | -1.34% | -97.75% |
Average DrawdownAverage peak-to-trough decline | -70.16% | -3.52% | -66.64% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 60.56% | 1.44% | +59.12% |
Volatility
ACXP vs. CLSE - Volatility Comparison
Acurx Pharmaceuticals, Inc. (ACXP) has a higher volatility of 20.58% compared to Convergence Long/Short Equity ETF (CLSE) at 3.24%. This indicates that ACXP's price experiences larger fluctuations and is considered to be riskier than CLSE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ACXP | CLSE | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 20.58% | 3.24% | +17.34% |
Volatility (6M)Calculated over the trailing 6-month period | 120.16% | 10.80% | +109.36% |
Volatility (1Y)Calculated over the trailing 1-year period | 185.91% | 13.79% | +172.12% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 139.94% | 13.86% | +126.08% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 139.84% | 13.86% | +125.98% |
Dividends
ACXP vs. CLSE - Dividend Comparison
ACXP has not paid dividends to shareholders, while CLSE's dividend yield for the trailing twelve months is around 0.77%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
ACXP Acurx Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
CLSE Convergence Long/Short Equity ETF | 0.77% | 0.95% | 0.93% | 1.21% | 0.85% |
Frequently Asked Questions
ACXP and CLSE have a correlation of 0.12, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ACXP has higher volatility (20.58%) compared to CLSE (3.24%). In terms of maximum drawdown, ACXP dropped -99.14% vs CLSE's -16.45%.
CLSE currently has the higher Sharpe Ratio (3.09 vs -0.42), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ACXP and CLSE
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer